BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT05064436
- Locations
- ๐บ๐ธ
Local Institution - 0001, Ann Arbor, Michigan, United States
๐ฌ๐งLocal Institution - 0002, London, United Kingdom
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05051553
- Locations
- ๐บ๐ธ
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
- Conditions
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT05044533
- Locations
- ๐ฌ๐ง
Local Institution - 0001, Swansea, United Kingdom
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
- Conditions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 350
- Registration Number
- NCT05034926
- Locations
- ๐ฌ๐ท
Local Institution - 0001, Athens, Greece
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
- Conditions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11776
- Registration Number
- NCT05027061
- Locations
- ๐ฏ๐ต
Local Institution, Tokyo, Japan
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT05025085
- Locations
- ๐บ๐ธ
Local Institution - 072, Cincinnati, Ohio, United States
๐บ๐ธMD Anderson Cancer Center Thoracic-Head & Neck Med Onc, Houston, Texas, United States
๐บ๐ธProvidence Cancer Institute, Portland, Oregon, United States
A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 17
- Registration Number
- NCT05014438
- Locations
- ๐ฉ๐ช
Private Practice - Dr. Ralph von Kiedrowski, Selters, Germany
๐บ๐ธLocal Institution - 0008, Skokie, Illinois, United States
๐บ๐ธLocal Institution - 0078, Philadelphia, Pennsylvania, United States
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT05005273
- Locations
- ๐ซ๐ท
Local Institution - 0044, Pessac, France
๐ซ๐ทLocal Institution - 0013, Suresnes, France
๐ซ๐ทLocal Institution - 0042, Toulon, France
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1050
- Registration Number
- NCT05002569
- Locations
- ๐บ๐ธ
Local Institution - 0191, Atlanta, Georgia, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธLocal Institution - 0164, Springdale, Arkansas, United States
Taste Assessment of Ozanimod
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT05001152
- Locations
- ๐บ๐ธ
Senopsys LLC, Woburn, Massachusetts, United States
๐บ๐ธLocal Institution - 0001, Woburn, Massachusetts, United States